We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

CULVER CITY, Calif., March 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. ImmunityBio markets Anktiva, a "novel IL-15 receptor ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing therapies and vaccines that support the natural immune system to defeat cancers and infectious diseases.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 69.46% +4.74, Direxion Daily ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...